13.01
2.40%
-0.32
Precedente Chiudi:
$13.33
Aprire:
$12.68
Volume 24 ore:
7.61M
Capitalizzazione di mercato:
$2.20B
Reddito:
$2.60B
Utile/perdita netta:
$-220.37M
Rapporto P/E:
-0.5276
EPS:
-24.66
Flusso di cassa netto:
$193.67M
1 W Prestazione:
+0.23%
1M Prestazione:
-13.55%
6M Prestazione:
-19.14%
1 anno Prestazione:
-49.51%
Teladoc Health Inc Stock (TDOC) Company Profile
Nome
Teladoc Health Inc
Settore
Industria
Telefono
203-635-2002
Indirizzo
2 Manhattanville Road, Suite 203, Purchase, NY
Teladoc Health Inc Stock (TDOC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-01-17 | Downgrade | DA Davidson | Buy → Neutral |
2024-01-03 | Iniziato | Barclays | Overweight |
2023-04-12 | Iniziato | Stephens | Equal-Weight |
2023-02-23 | Aggiornamento | SVB Securities | Market Perform → Outperform |
2022-10-24 | Aggiornamento | Guggenheim | Sell → Neutral |
2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2022-09-07 | Iniziato | Truist | Hold |
2022-08-17 | Downgrade | Guggenheim | Neutral → Sell |
2022-08-12 | Iniziato | DA Davidson | Buy |
2022-08-02 | Downgrade | Berenberg | Buy → Hold |
2022-08-02 | Downgrade | Cowen | Outperform → Market Perform |
2022-07-28 | Downgrade | Goldman | Buy → Neutral |
2022-07-28 | Downgrade | Needham | Buy → Hold |
2022-07-06 | Reiterato | BofA Securities | Neutral |
2022-05-05 | Downgrade | Argus | Buy → Hold |
2022-04-28 | Downgrade | Citigroup | Buy → Neutral |
2022-04-28 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-04-28 | Downgrade | Guggenheim | Buy → Neutral |
2022-04-28 | Downgrade | JP Morgan | Overweight → Neutral |
2022-04-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-04-28 | Downgrade | William Blair | Outperform → Mkt Perform |
2022-04-07 | Iniziato | Guggenheim | Buy |
2022-04-01 | Ripresa | Credit Suisse | Outperform |
2022-03-03 | Aggiornamento | Argus | Hold → Buy |
2022-02-23 | Reiterato | BofA Securities | Neutral |
2022-02-23 | Reiterato | Craig Hallum | Hold |
2022-02-23 | Reiterato | Evercore ISI | In-line |
2022-02-23 | Reiterato | Goldman | Buy |
2022-02-23 | Reiterato | JP Morgan | Overweight |
2022-02-23 | Reiterato | KeyBanc Capital Markets | Overweight |
2022-02-23 | Reiterato | Needham | Buy |
2022-02-23 | Reiterato | Oppenheimer | Outperform |
2022-02-23 | Reiterato | Stifel | Hold |
2022-02-11 | Iniziato | Goldman | Buy |
2022-02-08 | Reiterato | Piper Sandler | Overweight |
2021-12-02 | Ripresa | Jefferies | Hold |
2021-11-22 | Downgrade | BTIG Research | Buy → Neutral |
2021-10-28 | Reiterato | Barclays | Equal Weight |
2021-10-28 | Reiterato | BofA Securities | Neutral |
2021-10-28 | Reiterato | Canaccord Genuity | Buy |
2021-10-28 | Reiterato | Citigroup | Buy |
2021-10-28 | Reiterato | Craig Hallum | Hold |
2021-10-28 | Reiterato | Needham | Buy |
2021-10-28 | Reiterato | Oppenheimer | Outperform |
2021-10-28 | Reiterato | Piper Sandler | Overweight |
2021-10-28 | Reiterato | UBS | Neutral |
2021-10-19 | Iniziato | Wells Fargo | Overweight |
2021-08-02 | Downgrade | Argus | Buy → Hold |
2021-07-28 | Downgrade | Deutsche Bank | Buy → Hold |
2021-05-28 | Iniziato | Robert W. Baird | Neutral |
2021-04-15 | Iniziato | Needham | Buy |
2021-01-07 | Iniziato | BTIG Research | Buy |
2020-12-22 | Iniziato | Evercore ISI | In-line |
2020-12-07 | Downgrade | Stephens | Overweight → Equal-Weight |
2020-12-04 | Iniziato | Goldman | Neutral |
2020-11-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2020-09-22 | Iniziato | DA Davidson | Buy |
2020-09-02 | Aggiornamento | Berenberg | Hold → Buy |
2020-08-17 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2020-07-14 | Iniziato | Citigroup | Buy |
2020-07-13 | Iniziato | Argus | Buy |
2020-07-07 | Iniziato | Stephens | Overweight |
2020-04-30 | Reiterato | KeyBanc Capital Markets | Overweight |
2020-04-13 | Iniziato | SVB Leerink | Outperform |
2020-03-31 | Downgrade | Berenberg | Buy → Hold |
2020-03-25 | Downgrade | Craig Hallum | Buy → Hold |
2020-03-16 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-02-28 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
2020-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-01-10 | Iniziato | UBS | Neutral |
2020-01-09 | Downgrade | BofA/Merrill | Buy → Neutral |
Mostra tutto
Teladoc Health Inc Borsa (TDOC) Ultime notizie
Why Teladoc Health Stock Dived on Friday
The Motley Fool
13 Analysts Assess Teladoc Health: What You Need To Know
Benzinga
2 Bargain Growth Stocks to Buy Right Now
The Motley Fool
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Benzinga
Teladoc Health (TDOC) Q1 2024 Earnings Call Transcript
The Motley Fool
Teladoc (TDOC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Teladoc Health Inc Azioni (TDOC) Dati Finanziari
Teladoc Health Inc (TDOC) Reddito 2024
TDOC ha riportato un ricavo (TTM) di $2.60 miliardi per il trimestre terminato il 2023-12-31, un +8.13% salita anno su anno.
Teladoc Health Inc (TDOC) Reddito netto 2024
TDOC l'utile netto (TTM) è stato di -$220.37 milioni per il trimestre terminato il 2023-12-31, un +98.39% aumento anno su anno.
Teladoc Health Inc (TDOC) Flusso di cassa 2024
TDOC ha registrato un flusso di cassa disponibile (TTM) di $193.67 milioni per il trimestre conclusosi con 2023-12-31, un +1,072% aumento anno su anno.
Teladoc Health Inc (TDOC) Utile per azione 2024
L'utile per azione (TTM) di TDOC è stato pari a -$1.34 per il trimestre terminato il 2023-12-31, un +98.42% crescita anno su anno.
Capitalizzazione:
|
Volume (24 ore):